Biocon’s Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations

Bengaluru, India, November 12, 2018

“This is to inform you that the U.S. FDA conducted a pre approval inspection of our new Oral Solid Dosage Forms manufacturing facility at Biocon Park/ Bengaluru/ from Nov 05- Nov 09/ 2018. The audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to quality and cGMP compliance. N

– Company Spokesperson